Tofacitinib for RA Misses the Mark in Safety Study ...Middle East

Medscape - News
Daily treatment with tofacitinib led to more malignancies and adverse cardiovascular events in older rheumatoid arthritis patients compared with treatment with a tumor necrosis factor inhibitor. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( Tofacitinib for RA Misses the Mark in Safety Study )

Apple Storegoogle play

Also on site :

Most viewed in News